Verubecestat

Drug Profile

Verubecestat

Alternative Names: MK-8931; SCH-900931

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antidementias; Fluorobenzenes; Pyridines; Small molecules; Thiadiazines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 14 Feb 2017 Merck terminates the phase II/III EPOCH trial in Alzheimer's disease in Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Spain, South Korea, Turkey, USA and United Kingdom following the recommendation of the external Data Monitoring Committee (NCT01953601)
  • 02 Feb 2017 Merck and Co. completes enrolment in its phase III trial for Alzheimer's disease in USA, Canada, Australia, New Zealand, Japan, South Korea, United Kingdom, Austria, Belgium, Finland, France, Italy, Germany, Netherlands, Spain, Switzerland and Norway
  • 25 Nov 2016 Efficacy and adverse events data from a phase I trial in Alzheimer's disease released by Merck and Co.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top